Melanoma Treatment: ABP 206 vs. OPDIVO

We are evaluating a new treatment, ABP 206, for patients with advanced melanoma who have not been treated before. The study aims to see how well it works and how safe it is compared to OPDIVO.

>2 years >20 visits Confirmation phase (III)No Placebo Partially Remote Investigational Medicines InjectionOncology

What diseases are being studied?

Health conditions and diseases that the clinical trial is designed to study and treat.

Who can participate in the clinical trial?

These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..

What medicines are being studied?

Medicines that are officially approved for use in the European Union and considered safe by EMA. These medicines are already on the market and may be tested for new conditions or populations.

Opdivo

Opdivo is a cancer medicine that helps the immune system find and fight tumor cells.

What active substances are being studied?

Active substances that are officially approved for use in the European Union and considered safe by EMA. These substances are already on the market and may be tested for new conditions or populations.

Nivolumab

Nivolumab is a substance that helps the immune system recognize and attack certain cancers.

What experimental substances are being tested?

Experimental substances that are being investigated in this clinical trial. These are not yet approved for general use.

Abp 206

What similar medicines might you know?

Don't worry if you don't know the medicines tested in the trial. There is a chance you have heard about the similar medicines. Check the list below to see if you are familiar with any of them.

Opdualag

Where is the clinical trial being conducted?

Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.

Loading map...

Clinical Hospital Centre Osijek

93120004: Oncology

Osijek, Croatia

University Hospital Centre Zagreb

93120002: Oncology department

Zagreb, Croatia

Fakultni Nemocnice Hradec Kralove

93121002: Klinika onkologie a radioterap

Hradec Králové, Czechia

Sponsor: Amgen Inc.

Last updated: Nov 27, 2025

Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.